Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 17 Mar 2016 |
| Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL | 10 Mar 2016 |
| Genmab Announces European Regulatory Submission for Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL | 9 Mar 2016 |
| Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen | 9 Mar 2016 |
| Genmab Provides Update on Ofatumumab Development in Autoimmune Indications | 8 Mar 2016 |
| Genmab’s Total Number of Voting Rights and Total Share Capital | 29 Feb 2016 |